Latest Insider Transactions at Pliant Therapeutics, Inc. (PLRX)
This section provides a real-time view of insider transactions for Pliant Therapeutics, Inc. (PLRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PLIANT THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PLIANT THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Jan 04
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-13.79%
|
$285,000
$19.06 P/Share
|
|
Jan 04
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Jan 03
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-13.79%
|
$285,000
$19.33 P/Share
|
|
Jan 03
2023
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.12%
|
$30,000
$2.08 P/Share
|
|
Dec 22
2022
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+4.52%
|
$8,000
$2.08 P/Share
|
|
Dec 22
2022
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
2,928
-32.99%
|
$55,632
$19.38 P/Share
|
|
Dec 20
2022
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
8,748
-5.95%
|
$166,212
$19.1 P/Share
|
|
Dec 20
2022
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
4,719
-34.71%
|
$89,661
$19.1 P/Share
|
|
Dec 20
2022
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,887
-7.01%
|
$206,853
$19.1 P/Share
|
|
Dec 20
2022
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
34,212
-26.72%
|
$650,028
$19.1 P/Share
|
|
Dec 20
2022
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,643
-10.71%
|
$183,217
$19.1 P/Share
|
|
Dec 19
2022
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,578
+10.68%
|
-
|
|
Dec 19
2022
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
13,594
+50.0%
|
-
|
|
Dec 19
2022
|
Eric Lefebvre Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,876
+12.35%
|
-
|
|
Dec 19
2022
|
Bernard Coulie President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
68,751
+34.94%
|
-
|
|
Dec 19
2022
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,375
+17.7%
|
-
|
|
Nov 29
2022
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,000,000
-52.09%
|
-
|
|
Oct 25
2022
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.61%
|
$125,000
$25.05 P/Share
|
|
Sep 20
2022
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,000,000
-34.25%
|
-
|
|
Sep 12
2022
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
12,502
-17.42%
|
$275,044
$22.54 P/Share
|
|
Sep 12
2022
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,502
+14.83%
|
$25,004
$2.08 P/Share
|
|
Jul 12
2022
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
12,498
-17.41%
|
$274,956
$22.5 P/Share
|
|
Jul 12
2022
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,498
+14.83%
|
$24,996
$2.08 P/Share
|
|
Jul 11
2022
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,000
-2.12%
|
$60,000
$20.0 P/Share
|
|
Jul 11
2022
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-20.2%
|
$330,000
$22.5 P/Share
|
|
Jul 11
2022
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+16.8%
|
$30,000
$2.08 P/Share
|
|
Sep 03
2021
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+22.83%
|
$40,000
$2.08 P/Share
|
|
Jun 18
2021
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,500
-2.84%
|
$362,500
$29.43 P/Share
|
|
Jun 14
2021
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
4,000
-0.44%
|
$132,000
$33.33 P/Share
|
|
May 26
2021
|
Hans Hull Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+3.47%
|
$9,000
$2.08 P/Share
|
|
May 14
2021
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
3,500
-0.38%
|
$98,000
$28.91 P/Share
|
|
Apr 14
2021
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
3,500
-0.76%
|
$105,000
$30.33 P/Share
|
|
Apr 13
2021
|
Bernard Coulie President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+9.86%
|
$12,000
$2.08 P/Share
|
|
Mar 18
2021
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.88%
|
$487,500
$39.58 P/Share
|
|
Mar 15
2021
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
3,500
-0.25%
|
$133,000
$38.82 P/Share
|
|
Mar 05
2021
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+29.58%
|
$40,000
$2.08 P/Share
|
|
Feb 16
2021
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
3,500
-0.25%
|
$115,500
$33.01 P/Share
|
|
Jan 14
2021
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
3,500
-0.37%
|
$91,000
$26.71 P/Share
|
|
Dec 30
2020
|
Hans Hull Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+2.82%
|
$7,000
$2.08 P/Share
|
|
Dec 21
2020
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+14.01%
|
$9,000
$2.08 P/Share
|
|
Dec 18
2020
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.65%
|
$325,000
$26.58 P/Share
|
|
Dec 14
2020
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Indirect |
3,500
-0.37%
|
$94,500
$27.59 P/Share
|
|
Dec 01
2020
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,734
-27.66%
|
$543,286
$29.56 P/Share
|
|
Dec 01
2020
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,734
+19.81%
|
$74,936
$4.15 P/Share
|
|
Jun 05
2020
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,132,867
+50.0%
|
-
|
|
Jun 05
2020
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
5,559,440
+48.77%
|
-
|
|
Jun 05
2020
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,910,657
+50.0%
|
-
|